Transthyretin Amyloid Cardiomyopathy Clinical Trial

DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Summary

The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Males or females >18 years old
History of evidence suggestive of cardiac amyloidosis
Subject is willing and able to comply with protocol required assessments and provide written informed consent

Exclusion Criteria:

Known diagnosis of primary (AL) amyloidosis
Known diagnosis of hereditary cardiomyopathy or cardiomyopathy due to aortic stenosis
Patient is currently pregnant

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Estimated Enrollment:

1010

Study ID:

NCT02252653

Recruitment Status:

Completed

Sponsor:

Alnylam Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 19 Locations for this study

See Locations Near You

Clinical Trial Site
Little Rock Arkansas, , United States
Clinical Trial Site
Bakersfield California, , United States
Clinical Trial Site
La Mesa California, , United States
Clinical Trial Site
Los Angeles California, 90073, United States
Clinical Trial Site
Los Angeles California, 90095, United States
Clinical Trial Site
San Francisco California, , United States
Clinical Trial Site
Torrance California, , United States
Clinical Trial Site
Aurora Colorado, , United States
Clinical Trial Site
Washington District of Columbia, 20010, United States
Clinical Trial Site
Washington District of Columbia, 20052, United States
Clinical Trial Site
Washington District of Columbia, 20422, United States
Clinical Trial Site
Tampa Florida, , United States
Clinical Trial Site
Athens Georgia, , United States
Clinical Trial Site
Atlanta Georgia, 30303, United States
Clinical Trial Site
Atlanta Georgia, 30310, United States
Clinical Trial Site
Macon Georgia, , United States
Clinical Trial Site
Chicago Illinois, 60611, United States
Clinical Trial Site
Chicago Illinois, 60612, United States
Clinical Trial Site
Chicago Illinois, 60637, United States
Clinical Trial Site
Merrillville Indiana, , United States
Clinical Trial Site
Baltimore Maryland, , United States
Clinical Trial Site
Boston Massachusetts, , United States
Clinical Trial Site
Springfield Massachusetts, , United States
Clinical Trial Site
Detroit Michigan, , United States
Clinical Trial Site
Jackson Mississippi, , United States
Clinical Trial Site
St. Louis Missouri, , United States
Clinical Trial Site
Camden New Jersey, , United States
Clinical Trial Site
Bronx New York, , United States
Clinical Trial Site
Rochester New York, , United States
Clinical Trial Site
Rosedale New York, , United States
Clinical Trial Site
Williamsville New York, , United States
Clinical Trial Site
Durham North Carolina, , United States
Clinical Trial Site
Cleveland Ohio, , United States
Clinical Trial Site
Philadelphia Pennsylvania, 19102, United States
Clinical Trial Site
Philadelphia Pennsylvania, 19104, United States
Clinical Trial Site
Pittsburgh Pennsylvania, , United States
Clinical Trial Site
Charleston South Carolina, , United States
Clinical Trial Site
Fort Worth Texas, , United States
Clinical Trial Site
Plano Texas, , United States
Clinical Trial Site
Falls Church Virginia, , United States
Clinical Trial Site
Norfolk Virginia, , United States
Clinical Trial Site
Richmond Virginia, 23249, United States
Clinical Trial Site
Richmond Virginia, 23298, United States
Clinical Trial Site
Anderlecht , , Belgium
Clinical Trial Site
Brussels , 1020, Belgium
Clinical Trial Site
Hasselt , , Belgium
Clinical Trial Site
Roeselare , , Belgium
Clinical Trial Site
Blumenau , , Brazil
Clinical Trial Site
Bordeaux , , France
Clinical Trial Site
Toulouse Cedex , , France
Clinical Trial Site
Vandoeuvre-lès-Nancy , , France
Clinical Trial Site
Barcelona , 8003, Spain
Clinical Trial Site
Barcelona , 8907, Spain
Clinical Trial Site
Madrid , , Spain
Clinical Trial Site
Seville , , Spain
Clinical Trial Site
Cardiff , , United Kingdom
Clinical Trial Site
London , NW1 2, United Kingdom
Clinical Trial Site
London , SW17 , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Estimated Enrollment:

1010

Study ID:

NCT02252653

Recruitment Status:

Completed

Sponsor:


Alnylam Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider